2 active not recruiting, 2 terminated, 1 completed, 1 unknown. 7 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Active not recruiting 2, Terminated 2, Completed 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Terminated 2, Unknown 1 |
Follow urelumab: new trials by email Literature Review of urelumab trials Research Report on urelumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors Urelumab + Nivolumab - Neoplasms | Phase 1 / Phase 2 | Unknown | Clinica Universidad de Navarra, Universidad de Navarra | 32 | 2019-01-30 | 2019-01-03 |
| Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder Nivolumab in combination with Urelumab, Nivolumab monotherapy - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 15 | 2017-05-16 | 2026-04-06 |
| Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas Cyclophosphamide, GVAX pancreatic cancer, Nivolumab - Pancreatic Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 76 | 2016-03-28 | 2026-10-13 |
| Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients Rituximab, Urelumab - Leukemia | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2015-07-01 | 2016-12-06 | |
| An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Urelumab, Nivolumab - Advanced Solid Tumors, Advanced B-cell NHL | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 232 | 2014-09-29 | 2020-10-05 |
| Phase II, 2nd Line Melanoma - RAND Monotherapy Anti-CD137 (4-1BB) (BMS-663513) - Melanoma | Phase 2 | Completed | Bristol-Myers Squibb | 158 | 2008-03-01 | 2015-10-12 |
| Study of BMS-663513 in Patients With Advanced Cancer BMS-663513 - Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 115 | 2005-12-01 | 2015-10-12 |
Neoplasms (2) · Carcinoma, Transitional Cell (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Melanoma (1) · Pancreatic Neoplasms (1) · Recurrence (1) · Urinary Bladder Neoplasms (1)
Bristol-Myers Squibb (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · Clinica Universidad de Navarra, Universidad de Navarra (1) · M.D. Anderson Cancer Center (1)
United States (5) · France (3) · Canada (2) · Germany (2) · Spain (2) · Denmark (1) · Italy (1)
Ana De Jesus-Acosta, MD (1) · Nitin Jain, MBBS (1) · Noah Hahn, MD (1)
PMID 37339979, PMID 38458639, PMID 41543348
2014 (1), R01CA197296 (1)